Menopause Hormone Therapy: Benefits, Risks, and Who May Be a Candidate

Written by Kerri Rachelle, PhD(c), RDN, CSSD, FMP-AC
Founder & CEO, REV0lution | Doctor of Integrative & Natural Medicine Candidate

Quick Answer

Menopause hormone therapy—also called hormone replacement therapy or HRT—is the most effective established treatment for hot flashes and night sweats. It may also improve sleep when vasomotor symptoms are causing repeated awakenings, relieve vaginal and urinary symptoms, and help prevent bone loss while it is used.

Hormone therapy is not one medication. Its potential benefits and risks depend on the hormone, formulation, route, dose, timing, duration, whether a woman has a uterus and her individual health history. It should not be treated as a dangerous last resort, but it also should not be marketed as a universal prescription for longevity.

Hormone therapy may relieve symptoms. It cannot replace adequate nutrition, resistance training, restorative sleep, metabolic care or thoughtful alcohol use.

Key Takeaways

• Hormone therapy is the most effective established treatment for menopausal hot flashes and night sweats.

• Systemic and low-dose vaginal hormone therapies treat different problems and should not be discussed as though they are interchangeable.

• A woman with a uterus generally needs adequate endometrial protection when using systemic estrogen.

• Oral and transdermal estrogen do not carry identical risk profiles.

• Breast-cancer risk cannot be summarized accurately without distinguishing estrogen alone from estrogen combined with a progestogen.

• Age, time since menopause, personal history, formulation, route, dose and duration all matter.

• Hormone therapy should not be prescribed solely to prevent aging, dementia or cardiovascular disease.

• Women should not have to “earn” symptom relief by suffering through every lifestyle intervention first.

• Hormone therapy and foundational health habits solve different—although sometimes overlapping—problems.

• There is no universal age or treatment duration that applies to every woman.

What Is Menopause Hormone Therapy?

Menopause hormone therapy replaces hormones that become lower or more erratic during the menopause transition. It may include estrogen alone, estrogen combined with a progestogen, progesterone alone in selected situations or local vaginal estrogen.

“Hormone replacement therapy” remains the most frequently searched term, but many clinicians now use “menopause hormone therapy,” or MHT, because treatment is not necessarily attempting to restore a younger woman’s hormone levels. The goal is generally to relieve symptoms or address a specific clinical need using an individualized formulation and dose.

Systemic hormone therapy circulates throughout the body. It may be delivered through a pill, patch, gel, spray or another formulation. Low-dose vaginal estrogen is delivered directly to vaginal tissues and is primarily used for vaginal dryness, pain during sex and certain urinary symptoms.

These treatments are not interchangeable. A low-dose vaginal product used for local symptoms is clinically different from systemic estrogen used for hot flashes and night sweats.

What Symptoms Can Hormone Therapy Treat?

Systemic hormone therapy is the most effective established treatment for vasomotor symptoms—the hot flashes and night sweats that can interrupt work, exercise, relationships and sleep. It may also improve sleep when repeated temperature changes and night sweats are causing awakenings.

Hormone therapy may help some women with mood changes, joint discomfort or other symptoms that occur alongside the menopause transition, but those symptoms have multiple possible causes. Fatigue, anxiety, hair loss and difficulty regulating weight should not automatically be assigned to declining estrogen.

Before assuming that every symptom requires hormone treatment, it is important to consider thyroid dysfunction, iron deficiency, insulin resistance, inadequate nourishment, medication effects and sleep disorders. These overlapping possibilities are explored in Is It Perimenopause—or Something Else?.

Low-dose vaginal estrogen may help treat genitourinary syndrome of menopause, which can include vaginal dryness, burning, pain during sex, urinary urgency and recurrent urinary tract infections. Because systemic absorption is generally low, local therapy should be evaluated separately from systemic hormone therapy.

What Are the Potential Benefits of Hormone Therapy?

The clearest benefit is symptom relief. For a woman waking repeatedly with night sweats, struggling to function at work or avoiding intimacy because of pain, effective treatment can substantially improve quality of life.

Systemic hormone therapy also helps prevent bone loss while it is being used and can reduce fracture risk. This may be particularly important for women with premature ovarian insufficiency, early menopause or other risk factors for osteoporosis.

Oral micronized progesterone may improve certain sleep outcomes in some women. A systematic review of randomized trials found improvements in several measures of sleep, although most participants were postmenopausal and results were not identical across every outcome.

Benefits must still be tied to the woman’s actual treatment goal. Evidence that a therapy treats hot flashes does not automatically prove that every woman should use it to prevent cardiovascular disease, dementia or aging.

Why Does It Matter Whether a Woman Has a Uterus?

Systemic estrogen stimulates the endometrium—the lining of the uterus. When estrogen is used without adequate endometrial protection in a woman who still has a uterus, the risk of endometrial hyperplasia and endometrial cancer increases.

A progestogen is therefore generally included to protect the endometrium. “Progestogen” is the umbrella term that includes progesterone and synthetic progestins. These compounds are not necessarily identical in their effects, side-effect profiles or evidence bases.

Women who have had a hysterectomy may be able to use estrogen without a progestogen, depending on their medical history. This distinction partly explains why studies of estrogen alone cannot be casually combined with studies of estrogen plus a progestogen.

The FDA’s 2026 labeling changes retained the boxed warning concerning endometrial cancer for systemic estrogen used without adequate protection in women with a uterus. That warning reflects a well-established biological and clinical risk—not simply outdated fear.

Does the Route of Estrogen Matter?

Yes. Oral estrogen passes through the liver before entering systemic circulation. That first-pass effect influences clotting factors, triglycerides and other hepatic proteins.

Transdermal estrogen—delivered through a patch, gel or spray—bypasses much of that first-pass liver exposure. Observational evidence suggests transdermal estradiol may carry a lower risk of venous blood clots than oral estrogen, particularly at lower doses. That does not make it risk-free, but it means “estrogen risk” cannot be discussed accurately without identifying the route.

Oral estrogen may be appropriate for some women. Transdermal estrogen may be preferred in others, particularly when clotting, triglycerides, migraine or metabolic risk factors require consideration. That decision belongs with a qualified prescriber who understands the woman’s complete health history.

Does Hormone Therapy Cause Breast Cancer?

The most accurate answer is more nuanced than either “HRT causes breast cancer” or “HRT has no breast-cancer risk.”

Breast-cancer outcomes differ according to whether a woman uses estrogen alone or estrogen combined with a progestogen, the specific compounds used, treatment duration, baseline risk and the type of evidence being evaluated.

The Women’s Health Initiative trial using conjugated equine estrogens plus medroxyprogesterone acetate found a higher incidence of breast cancer with combined therapy. In the estrogen-alone trial involving women who had undergone hysterectomy, long-term follow-up did not show the same pattern and reported a lower incidence of breast cancer and breast-cancer mortality in that study population.

Those findings should not be interpreted as proof that all estrogen prevents breast cancer or that all combined therapy produces the same risk. The Women’s Health Initiative tested particular formulations in a particular population. Many participants were older and started treatment well after menopause, but that limitation does not justify discarding the trial.

The responsible conclusion is that breast-cancer risk must be discussed according to the actual regimen and the individual woman—not reduced to one frightening or reassuring sentence.

What About Blood Clots, Stroke, and Cardiovascular Risk?

Systemic hormone therapy can affect blood-clot and stroke risk, particularly when estrogen is taken orally. Absolute risk is generally lower in younger, healthier women than in women beginning therapy at an older age or further from menopause.

Current guidance commonly distinguishes women younger than 60 or within approximately 10 years of menopause onset from women starting systemic hormone therapy later. For many healthy women with bothersome symptoms in that earlier window, the benefit-risk balance is considered favorable. This is a general framework, not an automatic eligibility rule.

Hormone therapy should not be initiated solely to prevent cardiovascular disease. A woman’s blood pressure, lipid profile, glucose regulation, tobacco exposure, family history and history of blood clots, stroke or cardiovascular disease remain important.

Hormone therapy may influence certain biomarkers, but it does not erase the cardiovascular effects of smoking, poor nutrition, inadequate activity, unmanaged hypertension, insulin resistance or chronic sleep disruption.

What About Gallbladder Disease?

Oral hormone therapy may increase the risk of gallbladder disease, including gallstones and gallbladder inflammation. Because transdermal estrogen bypasses much of the first-pass processing through the liver, it may carry a lower gallbladder risk than oral estrogen.

Route matters for more than convenience. A history of gallstones, gallbladder disease, elevated triglycerides or other metabolic concerns should be included in the treatment conversation.

What Changed in the FDA Warnings?

In November 2025, the FDA initiated the removal of broad boxed warnings concerning cardiovascular disease, breast cancer and probable dementia from menopause hormone-therapy products. In February 2026, the agency began approving revised labeling for individual products.

This does not mean the FDA declared hormone therapy risk-free. Breast-cancer and cardiovascular information remains within product warnings and precautions. Systemic estrogen-alone products also retain the boxed warning about endometrial cancer when used by a woman with a uterus.

The change reflects recognition that previous class-wide warnings did not adequately communicate differences among women, formulations, routes and timing. It has also generated legitimate debate. Some experts believe the earlier warnings caused years of unnecessary fear and undertreatment. Others believe newer regulatory messaging risks overstating cardiovascular, cognitive or longevity benefits that have not been established in randomized trials.

REV0lution’s position is that neither regulatory era should substitute for individualized informed consent. Women deserve the actual evidence—including what remains uncertain.

Who May Be a Candidate for Menopause Hormone Therapy?

A woman may be a candidate if she has bothersome hot flashes, night sweats or other symptoms known to respond to hormone therapy and does not have a contraindication that makes systemic treatment inappropriate.

Women experiencing premature ovarian insufficiency or early menopause require particular attention because early loss of ovarian hormone exposure can affect bone and cardiovascular health. Hormone therapy is often considered until approximately the average age of natural menopause unless contraindicated.

Potential candidacy cannot be determined through an online symptom checklist. Important considerations include:

• Age and time since menopause

• Severity and type of symptoms

• Whether the uterus is present

• Unexplained vaginal bleeding

• Personal history of breast or endometrial cancer

• History of blood clots, stroke or cardiovascular disease

• Liver and gallbladder health

• Migraine history

• Blood pressure, triglycerides and metabolic health

• Family history

• Medication use

• Preferred route and treatment goals

A history that complicates systemic hormone use does not necessarily mean every form of local or nonhormonal treatment is unavailable. It means the conversation may require a clinician with specific menopause expertise.

When Does Hormone Therapy Require Additional Caution?

Unexplained vaginal bleeding should be evaluated before systemic hormone therapy is started. A history of breast cancer, estrogen-sensitive malignancy, blood clots, stroke, heart attack or active liver disease may change or limit the available options.

That does not mean women with complicated histories should be dismissed and told to endure symptoms. Nonhormonal prescription options exist, and certain local treatments may still be considered after individualized evaluation.

Evidence-based nonhormonal options may include certain antidepressants, gabapentin, fezolinetant and other treatments selected according to the symptom and the woman’s medical history. Cognitive behavioral therapy may also help reduce the degree to which vasomotor symptoms interfere with sleep and daily life.

These treatments deserve their own discussion. “Nonhormonal” does not automatically mean ineffective, side-effect-free or more natural.

Women should also disclose every hormone product they are already using, including creams, pellets, troches, over-the-counter progesterone products and compounded preparations. A clinician cannot accurately assess exposure without knowing the formulation and dose.

Does Hormone Therapy Replace Nutrition and Exercise?

No—but this should never be framed as requiring women to “work harder” before receiving symptom relief.

A woman does not need to perfect her diet, reach a particular weight or exhaust every natural intervention before discussing hormone therapy. Severe sleep disruption and vasomotor symptoms can make it harder to exercise, prepare food, regulate appetite or function during the day. Effective symptom treatment may help her reengage with those foundations.

At the same time, hormone therapy cannot provide adequate protein, build muscle without a training stimulus, correct iron deficiency, treat sleep apnea or neutralize the physiological effects of regular alcohol use.

This is especially important when hormone therapy improves sleep enough that everything appears resolved. Better sleep is meaningful. But it does not make a diet dominated by convenience products nutritionally complete, protect muscle without resistance training or eliminate the need to evaluate metabolic risk.

The strongest plan may include hormone therapy and lifestyle intervention rather than forcing women to choose one side. Learn more about the broader metabolic foundation in What Is Metabolic Health?.

How Can Women Reduce Risk While Using Hormone Therapy?

Risk reduction begins with selecting a treatment appropriate for the symptom. A woman experiencing only vaginal or urinary symptoms may not require systemic exposure. Another woman with severe hot flashes and night sweats may need a systemic option.

The hormone, route and dose should be individualized. The goal is to use an effective dose that adequately treats the symptom—not the highest dose a woman can tolerate or the lowest dose regardless of whether it works.

Follow-up should include more than renewing a prescription. Blood pressure, new bleeding, side effects, medication changes and evolving cardiovascular, breast, bone and metabolic risks should be reviewed. Women should also remain current with age- and risk-appropriate breast, cervical and bone-health screening. Hormone therapy does not replace routine preventive care.

Nutrition, movement, sleep, smoking cessation and alcohol reduction remain important because they affect risks that hormone therapy cannot independently control. This is not a demand for perfection. It is recognition that the treatment exists within an entire person.

How Long Should a Woman Stay on Hormone Therapy?

There is no universal duration that applies to every woman and no age at which all hormone therapy must automatically stop.

Treatment should be periodically reevaluated according to symptoms, goals, dose, route and evolving risk factors. Some women use systemic therapy for several years and discontinue it as symptoms change. Others continue longer after individualized discussion.

Hormone therapy is not addictive, but symptoms may return after it is discontinued. That can make stopping feel difficult, particularly when treatment restored sleep or daily functioning.

Evidence has not established that gradual tapering is always superior to stopping abruptly. Some women find tapering more manageable, but symptoms can recur with either approach. Cost, access, monitoring and the possibility of longer-term use should be discussed before treatment begins.

The Bottom Line

Menopause hormone therapy is neither a dangerous last resort nor a universal longevity prescription. It is an effective treatment with benefits and risks that depend on the woman, the symptom, the hormone, the route, the dose and the timing.

Women should not be frightened away from an appropriate treatment by oversimplified interpretations of older studies. They also should not be promised that hormones will prevent aging, dementia, cardiovascular disease or every consequence of menopause.

REV0lution’s role is to help women strengthen the health foundations that remain essential with or without hormone therapy: meaningful nourishment, muscle-preserving movement, metabolic health, restorative sleep and individualized care.

Hormones may help a woman feel like herself again. The rest of her health still deserves attention.

Medical Disclaimer: This article is for general educational and informational purposes only and does not provide individualized medical or nutrition advice. It is not intended to diagnose, treat, cure, or prevent disease or replace care from a qualified healthcare professional. Do not change your medications, supplements, diet, fasting schedule, or healthcare plan based solely on this content. [Read the full Medical Disclaimer and Terms & Conditions.]

Frequently Asked Questions

What is hormone replacement therapy?

Hormone replacement therapy, now commonly called menopause hormone therapy, uses estrogen, a progestogen or a combination of hormones to treat specific symptoms or health concerns associated with menopause. Systemic therapy circulates throughout the body, while low-dose vaginal therapy primarily treats vaginal and urinary symptoms.

Is hormone replacement therapy safe?

Hormone therapy can be an appropriate option for many healthy, symptomatic women, particularly those younger than 60 or within approximately 10 years of menopause onset. Safety depends on the hormone, dose, route, duration, uterus status and individual medical history. It is not one treatment with one universal risk profile.

What are the main benefits of hormone replacement therapy?

Systemic hormone therapy is the most effective established treatment for hot flashes and night sweats. It may improve sleep when vasomotor symptoms are causing awakenings and helps prevent bone loss while it is used. Low-dose vaginal estrogen can relieve vaginal dryness, painful sex and certain urinary symptoms.

Does hormone replacement therapy cause breast cancer?

Breast-cancer risk depends on the regimen. The Women’s Health Initiative found different outcomes for combined estrogen-progestin therapy and estrogen-alone therapy in women who had undergone hysterectomy. Risk also depends on the specific compounds, duration of use and the woman’s baseline risk. “HRT causes breast cancer” is too broad to be medically accurate, but claiming that all hormone therapy is free from breast-cancer risk is equally misleading.

Is a hormone patch safer than an oral hormone?

Transdermal estrogen bypasses much of the first-pass processing through the liver. Observational evidence suggests it may carry lower risks of blood clots and gallbladder disease than oral estrogen. That does not make a patch universally safer for every woman; the appropriate route depends on her symptoms and health history.

Do I need progesterone if I take estrogen?

A woman who still has a uterus generally needs adequate endometrial protection when using systemic estrogen. This is commonly provided with progesterone or another progestogen. Systemic estrogen used alone can stimulate the uterine lining and increase the risk of endometrial hyperplasia and cancer. Women who have had a hysterectomy may not require a progestogen.

Can hormone therapy help me sleep?

It may. Estrogen can improve sleep when hot flashes and night sweats are causing repeated awakenings. Research also suggests that oral micronized progesterone may improve certain sleep outcomes in some women. Persistent sleep problems should still be evaluated for insomnia, sleep apnea, restless legs, alcohol effects and other causes.

Can hormone replacement therapy help with weight loss?

Hormone therapy is not a weight-loss treatment. It may improve symptoms that indirectly affect appetite, movement and sleep, and it may influence body-fat distribution or help attenuate certain menopause-related body-composition changes. Meaningful fat loss and muscle preservation still depend on nutrition, resistance training, recovery, sleep and metabolic health.

Who should not take systemic hormone therapy?

Systemic hormone therapy may be inappropriate or require specialist evaluation in women with unexplained vaginal bleeding, certain estrogen-sensitive cancers, previous blood clots, stroke, heart attack, active liver disease or other significant risk factors. A complicated history does not mean a woman has no treatment options; local or nonhormonal therapies may still be appropriate.

What are the nonhormonal alternatives for hot flashes?

Evidence-based options may include certain antidepressants, gabapentin, fezolinetant and other prescription treatments selected according to the woman’s symptoms and medical history. Cognitive behavioral therapy and clinical hypnosis may reduce the disruption associated with vasomotor symptoms. Each option has its own benefits, limitations and potential adverse effects.

How long can a woman stay on hormone therapy?

There is no universal treatment duration or automatic stopping age. Therapy should be reevaluated periodically according to symptoms, dose, route, treatment goals and evolving risk factors. Some women discontinue after several years; others continue longer after individualized discussion with their prescriber.

Is hormone therapy difficult to stop?

Hormone therapy is not considered addictive, but the symptoms it was controlling may return after discontinuation. Research has not established that tapering is always better than stopping abruptly. Some women find a gradual reduction easier, but symptoms may recur with either approach.

Should women try lifestyle changes before hormone therapy?

Women should not be required to perfect their diet, lose weight or exhaust every lifestyle intervention before receiving appropriate symptom treatment. Nutrition, resistance training, sleep protection, alcohol reduction and metabolic care remain essential whether or not hormone therapy is used because hormones cannot perform those functions for the body.

What monitoring is needed while taking hormone therapy?

Follow-up should assess symptom response, blood pressure, side effects, new bleeding, medication changes and evolving breast, cardiovascular, bone and metabolic risks. Women should also remain current with age- and risk-appropriate preventive screening. Any unexpected bleeding after menopause requires medical evaluation.

References

The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. PMID: 35797481.

Makary MA, Mehta N. Updated labeling for menopausal hormone therapy. JAMA. 2026. PMID: 41212720.

Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380. PMID: 32721007.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. PMID: 12117397.

Prentice RL, Aragaki AK, Chlebowski RT, et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. American Journal of Epidemiology. 2021;190(3):365–375. PMID: 33025002.

Goldštajn MŠ, Mikuš M, Ferrari FA, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics. 2023;307(6):1727–1745. PMID: 35713694.

Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral versus transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism. 2015;100(11):4012–4020. PMID: 26544651.

Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thrombosis Research. 2018;168:83–95. PMID: 29936403.

Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386. PMID: 18617493.

Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. Journal of Clinical Endocrinology & Metabolism. 2021;106(4):e942–e951. PMID: 33245776.

Prior JC, Cameron A, Fung M, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a phase III Canada-wide randomized placebo-controlled four-month trial. Scientific Reports. 2023;13(1):9082. PMID: 37277418.

The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573–590. PMID: 37252752.

The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976–992. PMID: 32852449.

Panay N, Nappi RE, Palacios S, et al. Menopause and MHT in 2024: addressing the key controversies—an International Menopause Society White Paper. Climacteric. 2024;27(5):441–457. PMID: 39268862.